Discover a study exploring novel drug combinations and genetic insights transforming advanced bladder cancer treatment.

England's National Health Service will soon offer nivolumab as a quick injection for cancer patients. This new method cuts ...

Bladder Cancer Survival Better With Nivolumab Than Placebo in New Analysis. Neil Osterweil. February 21, 2025 . 0. Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease ...

To evaluate the activity and safety of nivolumab with nab-paclitaxel as neoadjuvant therapy, ... (RC) and postsurgical adjuvant nivolumab in patients with muscle-invasive bladder cancer (MIBC).

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

Source Reference: Mercinelli C, et al "First results of NURE-Combo: A phase II study of neoadjuvant nivolumab and nab-paclitaxel, followed by postsurgical adjuvant nivolumab, for muscle-invasive ...

Discover the latest updates to the EAU guidelines for muscle-invasive and metastatic bladder cancer in 2025. Learn more.

--CG Oncology, Inc., a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer ...

Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

In 2021, FDA approved nivolumab (Opdivo) as an adjuvant therapy for people with high-risk, muscle-invasive bladder cancer after a clinical trial showed that this immune checkpoint inhibitor - a ...

The approval also marks the fifth FDA-approved indication for nivolumab in 3 settings (neoadjuvant, adjuvant or perioperative) and across 4 cancer types (lung cancer, melanoma, bladder cancer and ...